Artykuły w czasopismach na temat „Hypoglycaemic agents”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Hypoglycaemic agents”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Mohajan, Devajit, and Haradhan Kumar Mohajan. "Oral Hypoglycaemic Agents: Non-Insulin Medications for Type 2 Diabetes Patients." Innovation in Science and Technology 3, no. 1 (2024): 23–31. http://dx.doi.org/10.56397/ist.2024.01.04.
Pełny tekst źródłaKermode, Allan G., Karen M. McNally, and David A. Joyce. "Sulphonylurea hypoglycaemic agents." Medical Journal of Australia 157, no. 10 (1992): 717–20. http://dx.doi.org/10.5694/j.1326-5377.1992.tb137447p.x.
Pełny tekst źródłaMarshall, SM. "Oral hypoglycaemic agents." Practical Diabetes International 20, no. 7 (2003): S1—S4. http://dx.doi.org/10.1002/pdi.524.
Pełny tekst źródła*, Dr. N. Tendu Pranadeep Dr. G. Gayathri Dr. B.Kavya Chowdary Dr.M.Anuhya Dr.C. Pradeep Dr. G. V. Nagaraju Dr.Md.K.Rahman Dr. Alias Kenny. "SAFETY AND EFFICACY OF TENELIGLIPTIN OVER OTHER HYPOGLYCEMIC AGENTS IN TYPE-2 DIABETES." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 07 (2018): 6325–40. https://doi.org/10.5281/zenodo.1310608.
Pełny tekst źródłaMacMahon, Clare, Millie O'Gorman, John Martin, et al. "249 Is Our Diabetic Control Too Tight? An Audit of Management of Type II Diabetes in a Long Term Care Setting." Age and Ageing 48, Supplement_3 (2019): iii17—iii65. http://dx.doi.org/10.1093/ageing/afz103.153.
Pełny tekst źródłaDr., Syed Farasat Ali Shah Dr. Eesha Noor Dr. Ifaza Tariq. "TO DETERMINE THE FREQUENCY OF HYPOGLYCAEMIA IN DIABETIC PATIENTS TAKING ORAL HYPOGLYCAEMIC DRUGS/ INSULIN." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 11 (2018): 12376–81. https://doi.org/10.5281/zenodo.1490073.
Pełny tekst źródłaNtouva, Antiopi, Konstantinos A. Toulis, Deepikshana Keerthy, et al. "Hypoglycaemia is associated with increased risk of fractures in patients with type 2 diabetes mellitus: a cohort study." European Journal of Endocrinology 180, no. 1 (2019): 51–58. http://dx.doi.org/10.1530/eje-18-0458.
Pełny tekst źródłaRosskamp, R. "Safety aspects of oral hypoglycaemic agents." Diabetologia 39, no. 12 (1996): 1668–72. http://dx.doi.org/10.1007/s001250050632.
Pełny tekst źródłaBatra, Chandar M., Kiran Kumar, and Monica Goyal. "D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring." Indian Journal of Endocrinology and Metabolism 26, Suppl 1 (2022): S1. http://dx.doi.org/10.4103/2230-8210.342324.
Pełny tekst źródłaMkele, Gail. "Where do sulphonylureas fit in the type 2 diabetes guidelines?" South African Family Practice 56, no. 4 (2014): 2. http://dx.doi.org/10.4102/safp.v56i4.4190.
Pełny tekst źródłaJian, Low Qin. "A Fatal Case of Metformin and Gliclazide Poisoning and its Management." Borneo Journal of Medical Sciences (BJMS) 11, no. 3 (2017): 35–40. http://dx.doi.org/10.51200/bjms.v11i3.978.
Pełny tekst źródłaMarchetti, Piero, and Renzo Navalesi. "Pharmacokinetic-Pharmacodynamic Relationships of Oral Hypoglycaemic Agents." Clinical Pharmacokinetics 16, no. 2 (1989): 100–128. http://dx.doi.org/10.2165/00003088-198916020-00004.
Pełny tekst źródłaHill, Jill. "Managing insulin resistance with oral hypoglycaemic agents." British Journal of Cardiac Nursing 2, no. 4 (2007): 182–87. http://dx.doi.org/10.12968/bjca.2007.2.4.23454.
Pełny tekst źródłaHellmuth, E., P. Damm, and L. Molsted-Pedersen. "Oral hypoglycaemic agents in 118 diabetic pregnancies." Diabetic Medicine 17, no. 7 (2000): 507–11. http://dx.doi.org/10.1046/j.1464-5491.2000.00314.x.
Pełny tekst źródłaSteel, J. M., and I. W. Campbell. "Oral hypoglycaemic agents in 188 diabetic pregnancies." Diabetic Medicine 18, no. 7 (2001): 604. http://dx.doi.org/10.1046/j.1464-5491.2001.00448-2.x.
Pełny tekst źródłaSteel, J. M., and I. W. Campbell. "Oral hypoglycaemic agents in 188 diabetic pregnancies." Diabetic Medicine 18, no. 7 (2001): 604. http://dx.doi.org/10.1046/j.1464-5491.2001.00448.x.
Pełny tekst źródłaPlank, Johannes, and Gerlies-Maria Bock. "Hypoglycaemic Agents for Type 2 Diabetes mellitus." Wiener Medizinische Wochenschrift 153, no. 21-22 (2003): 452–58. http://dx.doi.org/10.1007/s10354-003-0034-z.
Pełny tekst źródłaCalabuig, C., G. M. Antón-Fos, J. Gálvez, and R. Garcı́a-Doménech. "New hypoglycaemic agents selected by molecular topology." International Journal of Pharmaceutics 278, no. 1 (2004): 111–18. http://dx.doi.org/10.1016/j.ijpharm.2004.03.012.
Pełny tekst źródłaNabarro, John D. N. "Oral Hypoglycaemic Agents: The First Thirty Years." Journal of the Royal College of Physicians of London 26, no. 1 (1992): 50–55. https://doi.org/10.1016/s0035-8819(25)01883-5.
Pełny tekst źródłaHeller, Simon R., Milan S. Geybels, Ahmed Iqbal, Lei Liu, Lily Wagner, and Elaine Chow. "A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study." Diabetologia 65, no. 1 (2021): 55–64. http://dx.doi.org/10.1007/s00125-021-05556-7.
Pełny tekst źródłaAsfandiyarova, Nailya Sayfullaevna. "A review of mortality in type 2 diabetes mellitus." Diabetes mellitus 18, no. 4 (2015): 12–21. http://dx.doi.org/10.14341/dm6846.
Pełny tekst źródłaYOGEV, YARIV, and ODED LANGER. "THE USE OF ANTI-HYPERGLYCAEMIC AND HYPOGLYCAEMIC AGENTS IN PREGNANCY." Fetal and Maternal Medicine Review 15, no. 2 (2004): 133–43. http://dx.doi.org/10.1017/s096553950400124x.
Pełny tekst źródłaPatel, A. K., J. Kaur, D. K. Yadav, S. V. Rajendra, and M. Roy. "INFLUENCE OF FLUCONAZOLE ON HYPOGLYCAEMIC ACTIVITY OF ORAL ANTIDIABETIC AGENTS IN HEALTHY RATS." INDIAN DRUGS 54, no. 05 (2017): 50–55. http://dx.doi.org/10.53879/id.54.05.10614.
Pełny tekst źródłaDharini, Ravichandran, Sudeep Jain, Ragini Bhake, Vedavati B. Purandare, and Ambika G. Unnikrishnan. "Postbariatric Hypoglycaemia." Chronicle of Diabetes Research and Practice 4, no. 1 (2025): 49–53. https://doi.org/10.4103/cdrp.cdrp_15_24.
Pełny tekst źródłaHolstein, A., A. Plaschke, M. Ptak, et al. "Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents." British Journal of Clinical Pharmacology 60, no. 1 (2005): 103–6. http://dx.doi.org/10.1111/j.1365-2125.2005.02379.x.
Pełny tekst źródłaBennett, Stephen. "Oral hypoglycaemic agents: uses, actions and prescribing rationale." Nurse Prescribing 7, no. 7 (2009): 314–19. http://dx.doi.org/10.12968/npre.2009.7.7.43307.
Pełny tekst źródłaHolt, R. I. G., and K. D. Lambert. "The use of oral hypoglycaemic agents in pregnancy." Diabetic Medicine 31, no. 3 (2014): 282–91. http://dx.doi.org/10.1111/dme.12376.
Pełny tekst źródłaYukio, Ozaki, Yatomi Yutaka, and Kume Shoji. "Effects of oral hypoglycaemic agents on platelet functions." Biochemical Pharmacology 44, no. 4 (1992): 687–91. http://dx.doi.org/10.1016/0006-2952(92)90404-7.
Pełny tekst źródłaBatra, C. M., Savita Jain1, P. Kiran Kumar2, Monika Goyal3, and Varsha Kachroo4. "Abstract 17: Spontaneous hypoglycaemia due to insulin autoimmune syndrome in five cases, response to steroid therapy and rituximab." Indian Journal of Endocrinology and Metabolism 26, Suppl 1 (2022): S12. http://dx.doi.org/10.4103/2230-8210.342131.
Pełny tekst źródłaLindo, Ruby Alexander, Coleen Salmon, and Donovan Mcgrowder. "THE HYPOGLYCAEMIC EFFECT OF OLEANONIC ACID ISOLATED FROM PILEA ELIZABETHAE IN A RAT MODEL." International Journal of Current Pharmaceutical Research 9, no. 6 (2017): 63. http://dx.doi.org/10.22159/ijcpr.2017v9i6.23431.
Pełny tekst źródłaRowe, BethR, John Thorpe, and Anthony Barnett. "Safety of fluconazole in women taking oral hypoglycaemic agents." Lancet 339, no. 8787 (1992): 255–56. http://dx.doi.org/10.1016/0140-6736(92)90072-b.
Pełny tekst źródłaPogorelova, A. S. "A review of the efficacy and safety of the finished fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes mellitus." Medical Council, no. 12 (July 29, 2018): 118–26. http://dx.doi.org/10.21518/2079-701x-2018-12-118-126.
Pełny tekst źródłaLoh, K. C., and M. K. S. Leow. "Current Therapeutic Strategies for Type 2 Diabetes Mellitus." Annals of the Academy of Medicine, Singapore 31, no. 6 (2002): 722–30. https://doi.org/10.47102/annals-acadmedsg.v31n6p722.
Pełny tekst źródłaDi, Yuan Ming, Lu Sun, Chuanjian Lu, et al. "Benefits of herbal formulae containing Poria cocos (Fuling) for type 2 diabetes mellitus: A systematic review and meta-analysis." PLOS ONE 17, no. 12 (2022): e0278536. http://dx.doi.org/10.1371/journal.pone.0278536.
Pełny tekst źródłaHo, Francis LW, Choon-Fong Liew, Elaine C. Cunanan, and Kok-Onn Lee. "Oral Hypoglycaemic Agents for Diabetes in Pregnancy – An Appraisal of the Current Evidence for Oral Anti-diabetic Drug Use in Pregnancy." Annals of the Academy of Medicine, Singapore 36, no. 8 (2007): 672–78. http://dx.doi.org/10.47102/annals-acadmedsg.v36n8p672.
Pełny tekst źródłaTsang, Man-Wo. "The Management of Type 2 Diabetic Patients with Hypoglycaemic Agents." ISRN Endocrinology 2012 (May 7, 2012): 1–9. http://dx.doi.org/10.5402/2012/478120.
Pełny tekst źródłaGame, Fran. "Novel Hypoglycaemic Agents: Considerations in Patients with Chronic Kidney Disease." Nephron Clinical Practice 126, no. 1 (2014): 14–18. http://dx.doi.org/10.1159/000357680.
Pełny tekst źródłaKalashnikova, Marina Fedorovna, Dmitriy Yur'evich Belousov, Yury Ivanovich Suntsov, Maria Alexeevna Kantemirova, and Ivan Ivanovich Dedov. "Pharmacoepidemiological and pharmacoeconomic analyses of the utilization of hypoglycaemic drugs in patients with type 2 diabetes mellitus in Moscow." Diabetes mellitus 18, no. 2 (2015): 32–46. http://dx.doi.org/10.14341/dm2015232-46.
Pełny tekst źródłaMartin, G., and J. Rand. "Current Understanding of Feline Diabetes: Part 2, Treatment." Journal of Feline Medicine and Surgery 2, no. 1 (2000): 3–17. http://dx.doi.org/10.1053/jfms.2000.0057.
Pełny tekst źródłaBen-David, Eyal, Richard Hull, and Debasish Banerjee. "Diabetes mellitus in dialysis and renal transplantation." Therapeutic Advances in Endocrinology and Metabolism 12 (January 2021): 204201882110486. http://dx.doi.org/10.1177/20420188211048663.
Pełny tekst źródłaMadar, Zecharia, and Aliza H. Stark. "New legume sources as therapeutic agents." British Journal of Nutrition 88, S3 (2002): 287–92. http://dx.doi.org/10.1079/bjn2002719.
Pełny tekst źródłaNedosugova, Lyudmila Viktorovna, Nina Alexandrovna Petunina, and Karina Oganesovna Galstyan. "Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia." Diabetes mellitus 17, no. 4 (2014): 81–86. http://dx.doi.org/10.14341/dm2014481-86.
Pełny tekst źródłaKabade, Durgaprasad M., Anand Koppad, Ameet Khatawkar, Savitri D. Kabade, and Afaq Ahmed. "ORAL HYPOGLYCAEMIC AGENTS IN THE MANAGEMENT OF TYPE II DIABETES MELLITUS." Journal of Evidence Based Medicine and Healthcare 3, no. 45 (2016): 2272–82. http://dx.doi.org/10.18410/jebmh/2016/503.
Pełny tekst źródłaGnudi, Luigi, and Janaka Karalliedde. "Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents." Nephrology Dialysis Transplantation 31, no. 7 (2015): 1036–43. http://dx.doi.org/10.1093/ndt/gfv093.
Pełny tekst źródłaDatar, Prasanna A., and Sonali R. Jadhav. "Design and Synthesis of Pyrazole-3-one Derivatives as Hypoglycaemic Agents." International Journal of Medicinal Chemistry 2015 (February 4, 2015): 1–10. http://dx.doi.org/10.1155/2015/670181.
Pełny tekst źródłaSkett, P., and A. H. Hussin. "A direct action of oral hypoglycaemic agents on the rat liver?" European Journal of Pharmacology 183, no. 2 (1990): 287. http://dx.doi.org/10.1016/0014-2999(90)93140-l.
Pełny tekst źródłaNicholson, Wanda, and Kesha Baptiste-Roberts. "Oral hypoglycaemic agents during pregnancy: The evidence for effectiveness and safety." Best Practice & Research Clinical Obstetrics & Gynaecology 25, no. 1 (2011): 51–63. http://dx.doi.org/10.1016/j.bpobgyn.2010.10.018.
Pełny tekst źródłaPontiroli, Antonio E., Anna Caiderara, and Guido Pozza. "Secondary failure of oral hypoglycaemic agents: Frequency, possible causes, and management." Diabetes / Metabolism Reviews 10, no. 1 (1994): 31–43. http://dx.doi.org/10.1002/dmr.5610100104.
Pełny tekst źródłaWinocour, Peter H., Karen Moore-Haines, Keith Sullivan, Anne Currie, Andrew Solomon, and Dawn Hardy. "HbA1c in a primary care cohort with diabetes and chronic kidney disease: the East and North Hertfordshire Institute of Diabetes and Endocrinology (ENHIDE) Diabetes Renal Telehealth Project." British Journal of Diabetes 20, no. 2 (2020): 130–37. http://dx.doi.org/10.15277/bjd.2020.252.
Pełny tekst źródłaGoyal, Rajan, Himanshu Jindal, Abhilasha Singh, and Abhishek Kamendu. "Evaluation of Pattern of Use of Prescribed Oral Hypoglycaemic Drugs in Newly Diagnosed Diabetic Nephropathy Patients Visiting a Tertiary Care Hospital of Southern Bihar." Journal of Evidence Based Medicine and Healthcare 7, no. 43 (2020): 2492–96. http://dx.doi.org/10.18410/jebmh/2020/515.
Pełny tekst źródła